Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
BIOMARKER:
PBRM1 mutation
i
Other names:
PBRM1, Polybromo 1, BAF180
Associations
(16)
News
Trials
B | Sensitive
C3 | Sensitive
D | Sensitive
B | Resistant
C3 | Resistant
D | Resistant
Show legend
Include preclinical:
Drug categories
Immunotherapy
CD Protein Inhibitors
Immune Checkpoint Inhibitors
Tyrosine Kinase Inhibitors
FGF
Serine-Threonine Kinase Inhibitors
Chemotherapy
DNA
Epigenetics
BCL Inhibitors
Cancel
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Bladder Cancer
Cholangiocarcinoma
Biliary Tract Cancer
Chordoma
Lung Adenocarcinoma
Non Small Cell Lung Cancer
everolimus
C3
PBRM1 mutation
|
Renal Cell Carcinoma
|
everolimus
pembrolizumab
C3
PBRM1 mutation
|
Bladder Cancer
|
pembrolizumab
durvalumab
C3
PBRM1 mutation
|
Biliary Tract Cancer
|
durvalumab
FF-10502
C3
PBRM1 mutation
|
Cholangiocarcinoma
|
FF-10502
nivolumab
C3
PBRM1 mutation
|
Clear Cell Renal Cell Carcinoma
|
nivolumab
pembrolizumab + lenvatinib
C3
PBRM1 mutation
|
Renal Cell Carcinoma
|
pembrolizumab + lenvatinib
PRT1419
D
PBRM1 mutation
|
Renal Cell Carcinoma
|
PRT1419
bevacizumab + atezolizumab
C3
PBRM1 mutation
|
Renal Cell Carcinoma
|
bevacizumab + atezolizumab
atezolizumab
C3
PBRM1 mutation
|
Renal Cell Carcinoma
|
atezolizumab
tazemetostat
D
PBRM1 mutation
|
Chordoma
|
tazemetostat
Immunotherapy
B
PBRM1 mutation
|
Clear Cell Renal Cell Carcinoma
|
Immunotherapy
C3
PBRM1 mutation
|
Renal Cell Carcinoma
|
Immunotherapy
C3
PBRM1 mutation
|
Bladder Cancer
|
Immunotherapy
C3
PBRM1 mutation
|
Lung Adenocarcinoma
|
Immunotherapy
C3
PBRM1 mutation
|
Non Small Cell Lung Cancer
|
Immunotherapy
PD1 inhibitor
C3
PBRM1 mutation
|
Clear Cell Renal Cell Carcinoma
|
PD1 inhibitor
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
